Blood cancer drug fails to show promise in Post-Transplant trial
NCT ID NCT05127174
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested the drug fedratinib (Inrebic) as a maintenance therapy to prevent relapse in people with myeloproliferative neoplasms after a stem cell transplant. Only 12 participants were enrolled before the study was terminated. The goal was to find a safe dose and see if it could improve survival, but the early stop means results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fedratinib (Inrebic), a pill taken daily
What this could lead to
If it had worked, this could point toward a way to keep blood cancers from coming back after a stem cell transplant.
What could go wrong
The trial was very small (12 people) and was terminated early, so we don't have enough data to know if it's safe or effective. Fedratinib can cause side effects like nausea and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States